Discover 778 paid clinical trials in Toledo, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 778
FeaturedActive & Responsive
Weight Loss Studies for Adults With a BMI of 27+, Including People Managing Type 2 Diabetes or Sleep Apnea
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for
Non-Small Cell Lung Cancer, c-MET
Location: Perrysburg OH, Zanesville OH, Chicago IL, Niles IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06568939
Phase 2, Recruiting
Featured
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Ann Arbor MI, London, Cincinnati OH, Amherst NY,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase 3, Recruiting
Featured
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
for
Metastatic Colorectal Cancer
Location: Ann Arbor MI, London, Cincinnati OH, Chicago IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06820463
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Ann Arbor MI, Columbus OH, Chicago IL, Warrenville IL,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT04302025
Phase 2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Location: Ann Arbor MI, Detroit MI, Clinton Township MI,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18 - 70+
Code: NCT06419374
Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Detroit MI, Hilliard OH, Pittsburgh PA, Morgantown WV,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase 2, Recruiting
Featured
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: Detroit ME, Cleveland OH, Canton OH, Pittsburgh PA,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase 1, Phase 2, Recruiting
Featured
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
for
Non Small Cell Lung Carcinoma, c-MET
Location: Detroit MI, Fort Wayne IN, Columbus OH, Hinsdale IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06772623
Phase 1, Phase 2, Recruiting
Featured
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Detroit MI, Fort Wayne IN, Cleveland OH, Lexington KY,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07155174
Phase 2, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Detroit MI, Cleveland OH, Mayfield Heights OH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase 3, Recruiting
Featured
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
for
Crohn's Disease
Location: Novi MI, Columbus OH, London, Cincinnati OH,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT06548542
Phase 2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for
Parkinson's Disease
Location: Farmington Hills MI, Cleveland OH, Canton OH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07174310
Phase 3, Recruiting
Featured
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
for
Alzheimers Disease
Location: Farmington Hills MI, Columbus OH, London, Chicago IL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07177352
Phase 3, Recruiting
Active & Responsive
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
for
Acute Ischemic Stroke
Location: Toledo OH, Mount Clemens MI, Lansing MI, Flint MI,
Sponsor: Mercy Health Ohio
Sex: All
Age: 18 - 70+
Code: NCT05611242
Phase 3, Recruiting
Active & Responsive
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
for
Pulmonary Nodule, Solitary, Lung Cancer
Location: Toledo OH, Cincinnati OH, Chicago IL, Lexington KY,
Sponsor: Veracyte, Inc.
Sex: All
Age: 29 - 70+
Code: NCT06426628
Recruiting
Active & Responsive
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Toledo OH, Maumee OH, Monroe MI, Adrian MI,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05929768
Phase 3, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention